ELLIOT MYERS: Open Payments
NPI 1528481587 · CARENCRO, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,799 in 83 payments from 16 companies in 2025. Trend: 2023 $499 · 2024 $681 · 2025 $1,799
Food & beverage: $1,682Education: $117
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 12 | $276 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $262 |
| Axsome Therapeutics, Inc. | 12 | $261 |
| Vanda Pharmaceuticals Inc. | 8 | $188 |
| E.R. Squibb & Sons, L.L.C. | 5 | $185 |
| Teva Pharmaceuticals USA, Inc. | 5 | $159 |
| ABBVIE INC. | 6 | $115 |
| Supernus Pharmaceuticals, Inc. | 5 | $81 |
| Neurocrine BioSciences, Inc. | 2 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
Products named: ARISTADA, CAPLYTA, Auvelity, COBENFY, FANAPT, VRAYLAR, Qelbree, REXULTI.
Industry payments across LA — which companies pay providers there.
